@article {1171, title = {Reduced Dose Methotrexate and Mycophenolate Mofetil in Noninfectious Uveitis: A Sub-Analysis from the First-Line Antimetabolites as Steroid Sparing Therapy (FAST) Trial.}, journal = {Ocul Immunol Inflamm}, year = {2023}, month = {2023 Jan 26}, pages = {1-6}, abstract = {

PURPOSE: Some patients taking methotrexate (MTX) or mycophenolate mofetil (MMF) experience intolerable side effects at full doses. We evaluated whether dose reduction affected treatment outcomes in uveitis patients.

METHODS: Subanalysis of the First-line Antimetabolites as Steroid-sparing Treatment (FAST) uveitis trial. Patients were randomized to receive MTX (25 mg weekly) or MMF (3\ g daily). A pre-specified dose reduction protocol could be employed for intolerable side effects. Primary analysis was performed at 6\ months.

RESULTS: 43/194 patients (22\%) required dose reduction. 88/151 patients (58\%) on maximum doses and 32/43 patients (74\%) on reduced doses were deemed treatment successes at 6 months. The odds ratio point estimate (1.60, 95\% CI 0.72-3.74) favored dose-reduction but this was not significant. Following reduction, adverse events improved at the subsequent study visit (79 events reduced to 63 events).

CONCLUSION: Dose reduction of antimetabolites was not associated with worse outcomes in this subanalysis of a uveitis trial.

}, issn = {1744-5078}, doi = {10.1080/09273948.2023.2165949}, author = {Sura, Amol A and Sun, Yuwei and Reddy, Amit K and Rathinam, S R and Gonzales, John A and Thundikandy, Radhika and Vedhanayaki, Rajesh and Kanakath, Anuradha and Murugan, Bala and Doan, Thuy A and Lim, Lyndell L and Suhler, Eric B and Al-Dhibi, Hassan A and Acharya, Nisha R} }